196 related articles for article (PubMed ID: 37895229)
41. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
42. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
[TBL] [Abstract][Full Text] [Related]
43. HSH2D contributes to methotrexate resistance in human T‑cell acute lymphoblastic leukaemia.
Wang J; Xiong Y
Oncol Rep; 2020 Nov; 44(5):2121-2129. PubMed ID: 33000278
[TBL] [Abstract][Full Text] [Related]
44. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance.
Catts VS; Farnsworth ML; Haber M; Norris MD; Lutze-Mann LH; Lock RB
Leukemia; 2001 Jun; 15(6):929-35. PubMed ID: 11417479
[TBL] [Abstract][Full Text] [Related]
45. Sensitization to Drug Treatment in Precursor B-Cell Acute Lymphoblastic Leukemia Is Not Achieved by Stromal NF-κB Inhibition of Cell Adhesion but by Stromal PKC-Dependent Inhibition of ABC Transporters Activity.
Ruiz-Aparicio PF; Uribe GI; Linares-Ballesteros A; Vernot JP
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500796
[TBL] [Abstract][Full Text] [Related]
46. A combination of methotrexate and irradiation promotes cell death in NK/T-cell lymphoma cells via down-regulation of NF-κB signaling.
Kim A; Lee JE; Jang WS; Lee SJ; Park S; Kang HJ; Lee SS
Leuk Res; 2012 Mar; 36(3):350-7. PubMed ID: 21893341
[TBL] [Abstract][Full Text] [Related]
47. Glutamic Acid Increased Methotrexate Polyglutamation and Cytotoxicity in a CCRF-SB Acute Lymphoblastic Leukemia Cell Line.
Mendoza-Santiago A; Becerra E; Garay E; Bah M; Berumen-Segura L; Escobar-Cabrera J; Hernández-Pérez A; García-Alcocer G
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31779260
[No Abstract] [Full Text] [Related]
48. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.
Weigand M; Frei E; Graf N; Buchholz B; Wolfrom C; Breuer A; Wiessler M
J Cancer Res Clin Oncol; 1999; 125(8-9):513-9. PubMed ID: 10480345
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
Kodidela S; Suresh Chandra P; Dubashi B
Eur J Clin Pharmacol; 2014 Mar; 70(3):253-60. PubMed ID: 24370659
[TBL] [Abstract][Full Text] [Related]
51. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.
Trippett T; Schlemmer S; Elisseyeff Y; Goker E; Wachter M; Steinherz P; Tan C; Berman E; Wright JE; Rosowsky A
Blood; 1992 Sep; 80(5):1158-62. PubMed ID: 1381235
[TBL] [Abstract][Full Text] [Related]
52. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
53. NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia.
Tracey L; Streck CJ; Du Z; Williams RF; Pfeffer LM; Nathwani AC; Davidoff AM
Leukemia; 2010 Apr; 24(4):806-12. PubMed ID: 20130599
[TBL] [Abstract][Full Text] [Related]
54. Hepatoprotective effect of rhein against methotrexate-induced liver toxicity.
Bu T; Wang C; Meng Q; Huo X; Sun H; Sun P; Zheng S; Ma X; Liu Z; Liu K
Eur J Pharmacol; 2018 Sep; 834():266-273. PubMed ID: 30031796
[TBL] [Abstract][Full Text] [Related]
55. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro.
Hum MC; Smith AK; Lark RH; Winick NJ; Kamen BA
Pharmacotherapy; 1997; 17(6):1260-6. PubMed ID: 9399609
[TBL] [Abstract][Full Text] [Related]
56. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.
Wuchter C; Krappmann D; Cai Z; Ruppert V; Scheidereit C; Dörken B; Ludwig WD; Karawajew L
Leukemia; 2001 Jun; 15(6):921-8. PubMed ID: 11417478
[TBL] [Abstract][Full Text] [Related]
57. Association of GGH Promoter Methylation Levels with Methotrexate Concentrations in Chinese Children with Acute Lymphoblastic Leukemia.
Wang SM; Kong XY; Li M; Sun LL; Yan D
Pharmacotherapy; 2020 Jul; 40(7):614-622. PubMed ID: 32476160
[TBL] [Abstract][Full Text] [Related]
58. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.
Belkov VM; Krynetski EY; Schuetz JD; Yanishevski Y; Masson E; Mathew S; Raimondi S; Pui CH; Relling MV; Evans WE
Blood; 1999 Mar; 93(5):1643-50. PubMed ID: 10029593
[TBL] [Abstract][Full Text] [Related]
59. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
60. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
Refsum H; Wesenberg F; Ueland PM
Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
